Marco Donia

Marco Donia publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Marco Donia sits on this spectrum.

Marco Donia D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Marco Donia sits on this spectrum.

Best Publications

• Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

  Rita Cabrita;Martin Lauss;Adriana Sanna;Marco Donia

  2148
  Citations

• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf

  691
  Citations

• Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

  Unknown

  571
  Citations

• Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

  Martin Lauss;Marco Donia;Katja Harbst;Rikke Andersen

  502
  Citations

• Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

  Erlend Strønen;Erlend Strønen;Mireille Toebes;Sander Kelderman;Marit M. Van Buuren

  496
  Citations

• Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

  Sine Reker Hadrup;Marco Donia;Per Thor Straten

  395
  Citations

• Collagen density regulates the activity of tumor-infiltrating T cells

  Dorota E. Kuczek;Anne Mette Hvid Larsen;Anne Mette Hvid Larsen;Marie-Louise Thorseth;Marco Carretta

  381
  Citations

• Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

  Amalie Kai Bentzen;Andrea Marion Marquard;Rikke Lyngaa;Sunil Kumar Saini

  362
  Citations

• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

  Rikke Andersen;Marco Donia;Eva Ellebaek;Troels Holz Borch

  323
  Citations

• Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

  Michael D. Crowther;Garry Dolton;Mateusz Legut;Marine E. Caillaud

  244
  Citations

• Principles of adoptive T cell therapy in cancer.

  Özcan Met;Özcan Met;Kasper Mølgaard Jensen;Christopher Aled Chamberlain;Marco Donia

  224
  Citations

• Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

  Eva Ellebaek;Trine Zeeberg Iversen;Niels Junker;Marco Donia;Marco Donia

  204
  Citations

• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

  Unknown

  197
  Citations

• Dissection of T cell antigen specificity in human melanoma

  Rikke Sick Andersen;Charlotte Albæk Thrue;Niels Junker;Rikke Birgitte Lyngaa

  194
  Citations

• Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

  Henrik Jespersen;Mattias F. Lindberg;Marco Donia;Elin M. V. Söderberg

  166
  Citations

• The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

  Stephen L. Abrams;Linda S. Steelman;John G. Shelton;Ellis W.T. Wong

  159
  Citations

• Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

  M.H. Geukes Foppen;M. Donia;I.M. Svane;J.B.A.G. Haanen

  156
  Citations

• More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers

  Garry Michael Dolton;Katie Tungatt;Angharad Lloyd;Valentina Bianchi

  154
  Citations

• Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

  Marco Donia;Marco Donia;Rikke Andersen;Julie Westerlin Kjeldsen;Paolo Fagone

  150
  Citations

• Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

  Unknown

  131
  Citations